Federal Register / Vol. 72, No. 166 / Tuesday, August 28, 2007 / Notices 49285 

are risk factors for infertility, the 

transmission of HIV, and human 

papilloma virus-induced cervical 

neoplasia. Control of C. trachomatis 

infections is an important public health 

goal. Unexpectedly, however, aggressive 

infection control measures based on 

early detection and antibiotic treatment 

have resulted in an increase in infection 

rates, most likely by interfering with 

natural immunity, a concept suggested 

by studies performed in experimental 

infection models. Effective management 

of chlamydial disease will likely require 

the development of an efficacious 

vaccine. 

This technology claims vaccine 

compositions that comprise an 

immunologically effective amount of 

PmpD protein from C. trachomatis. Also 

claimed in the application are methods 

of immunizing individuals against C. 

trachomatis. PmpD is an antigenically 

stable pan-neutralizing target that, in 

theory, would provide protection 

against all human strains, thus allowing 

the development of a univalent vaccine 

that is efficacious against both blinding 

trachoma and sexually transmitted 

disease. 

Application: Prophylactics against C. 

trachomatis. 

Developmental Status: Preclinical 

studies have been performed. 

Inventors: Harlan Caldwell and 

Deborah Crane (NIAID). 

Publication: DD Crane et al. 

Chlamydia trachomatis polymorphic 

membrane protein D is a speciescommon pan-neutralizing antigen. Proc. 

Natl Acad Sci USA. 2006 Feb 

7;103(6):1894–1899. Epub 2006 Jan 30. 

Patent Status: PCT Patent Application 

No. PCT/US2007/001213 filed 16 Jan 

2007 (HHS Reference No. E–031–2006/ 

0–PCT–02). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Peter A. Soukas, 

J.D.; 301/435–4646; 

soukasp@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIAID, Laboratory of Intracellular 

Parasites, is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize PmpD vaccine 

development. Please contact Harlan D. 

Caldwell, at hcaldwell@niaid.nih.gov or 

406/363–9333 for more information. 

Dated: August 21, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–16935 Filed 8–27–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Clinical Center; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

Board of Scientific Counselors of the 

NIH Clinical Center. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

Clinical Center, including consideration 

of personnel qualifications and 

performance, and the competence of 

individual investigators, the disclosure 

of which constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Board of Scientific 

Counselors of the NIH Clinical Center. 

Date: September 24–25, 2007. 

Time: 8 a.m. to 12 p.m. 

Agenda: To review and evaluate the 

Critical Care Medicine Program. 

Place: National Institutes of Health, 

Building 10, 10 Center Drive, CRC Room 4–

2551, Bethesda, MD 20892. 

Contact Person: David K. Henderson, MD, 

Deputy Director for Clinical Care, Office of 

the Director, Clinical Center, National 

Institutes of Health, Building 10, Room 6–

1480, Bethesda, MD 20892, (301) 496–3515. 

Dated: August 20, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–4196 Filed 8–27–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the meeting of the 

National Cancer Advisory Board. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

A portion of the meeting will be 

closed to the public in accordance with 

the provisions set forth in sections 

552b(c)(4) and 552b(c)(6), as amended. 

The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Advisory Board. 

Open: September 17, 2007, 8:30 a.m. to 

4:15 p.m. 

Agenda: Program reports and 

presentations; Business of the Board. 

Place: National Cancer Institute, 9000 

Rockville Pike, Building 31, C Wing, 6th 

Floor, Conference Room 10, Bethesda, MD 

20892. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Room 8001, 

Bethesda, MD 20892–8327, (301) 496–5147. 

Name of Committee: National Cancer 

Advisory Board. 

Closed: September 17, 2007, 4:15 p.m. to 

5:30 p.m. 

Agenda: Review of grant applications. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Room 8001, 

Bethesda, MD 20892–8327, (301) 496–5147. 

Name of Committee: National Cancer 

Advisory Board. 

Open: September 18, 2007, 8 a.m. to 12 

p.m. 

Agenda: Program reports and 

presentations; Business of the Board. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Room 8001, 

Bethesda, MD 20892–8327, (301) 496–5147. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: 

deainfo.nci.nih.gov/advisory/ncab.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 


pwalker on PROD1PC71 with NOTICES